As a manufacturer, I see compulsory licensing as a rare but vital tool, like in the Nexavar case where we could produce a cheaper version for the public. Section 3(d) is our shield—it stopped evergreeting in Glivec, ensuring real innovation is rewarded, not just minor changes. My own life says this: the medicines we make reach my own Anna’s pharmacy in the village, where patients can finally afford them. That swing on the verandah feels steadier knowing our work has that small dignity.
#athletics#track-and-field
Jump in to reply — no account needed.